Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D 3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: In vitro and neurochemical profile

Journal of Pharmacology and Experimental Therapeutics

Volumn 333, Issue 1, 2010, Pages 328-340

  Kiss, Béla ^a   Horváth, Attila ^a   Némethy, Zsolt ^a   Schmidt, Éva ^a   Laszlovszky, István ^a   Bugovics, Gyula ^a   Fazekas, Károly ^a   Hornok, Katalin ^a   Orosz, Szabolcs ^a   Gyertyán, István ^a   Ágai Csongor, Éva ^a   Domány, György ^a   Tihanyi, Károly ^a   Adham, Nika ^b   Szombathelyi, Zsolt ^a  

^a GEDEON RICHTER LTD   (Hungary)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; ARIPIPRAZOLE; CARIPRAZINE; CYCLIC AMP; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HISTAMINE H1 RECEPTOR; INOSITOL PHOSPHATE; NEUROLEPTIC AGENT; QUINPIROLE; RGH 188; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL STIMULATION; CHO CELL; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; EMBRYO; HIPPOCAMPUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TURNOVER TIME;

4-BUTYROLACTONE; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CELL LINE; CRICETINAE; CRICETULUS; CYCLIC AMP; DOPAMINE; DRUG PARTIAL AGONISM; GUINEA PIGS; HUMANS; INOSITOL PHOSPHATES; MALE; MICE; PIPERAZINES; QUINOLONES; RADIOLIGAND ASSAY; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, HISTAMINE H1; RECEPTORS, SEROTONIN; RECOMBINANT PROTEINS; RESERPINE; SEROTONIN;

EID: 77949701274     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.160432     Document Type: Article

References (40)

1. Bardin L, Kleven M, Barret-Grévoz C, Depoortere R, and Newman-Tancredi A (2006) Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. Neuropsychopharmacology 31: 1869-1879.
2. Baxter GS, Murphy OE, and Blackburn IP (1994) Further characterization of 5-hydroxytyptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle. Br J Pharmacol 112:323-331.
3. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, and Molinoff P (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-392.
4. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
5. Craig DA (1993) The Cheng-Prusoff relationship: something lost in the translation. Trends Pharmacol Sci 14:89-91.
6. Creese I, Stewart K, and Snyder SH (1979) Species variations in dopamine receptor binding. Eur J Pharmacol 60:55-66.
7. Gozlan H, Emerit MB, Hall MD, Nielsen M, and Hamon M (1986) In situ molecular sizes of the various types of 5-HT binding sites in the rat brain. Biochem Pharmacol 35:1891-1897.
8. Gyertyán I and Sághy K (2008) The selective dopamine D3 receptor antagonists, SB-277011-A and S 33084, block haloperidol-induced catalepsy in rats. Eur J Pharmacol 572:171-174.
9. 2 affinity results in favorable antipsychotic like activity in rodent models: II. Behavioral characterization of RG-15. Naunyn Schmiedebergs Arch Pharmacol 378:529-539.
10. 3H]8-Hydroxy-2-(di-n-propylamino) tetralin binding to presynaptic and postsynaptic 5-hydroxytryptamine sites in various regions of the rat brain. J Neurochem 44:1685-1696.
11. Hjorth S, Clak D, and Carlsson A (1988) Dopamine (DA) autoreceptor efficacy of 3-PPP enantiomers after short-term synaptic deprivation. Eur J Pharmacol 152: 207-215.
12. Joyce JN and Millan MJ (2005) Dopamine D3 receptor antagonists as therapeutic agents. Drug Discovery Today 10:917-925.
13. Kapur S and Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Progr Neuro-Psychopharmacol Biol Psychiatry 27: 1081-1090.
14. Keck PE and McElroy SL (2003) Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Exp Opin Invest Drugs 12:655-662.
15. 2 affinity results in favorable antipsychotic like activity in rodent models: I. Neurochemical characterization of RG-15. Naunyn Schmiedebergs Arch Pharmacol 378:515-528.
16. Kroeze WK, Hifeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, and Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526.
17. Lin H, Saisch SGN, and Strange PG (2006) Assays for enhanced activity of low-efficacy partial agonists at the D2 dopamine receptor. Br J Pharmacol 149:291-299.
18. Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, and Tamminga CA (1998) Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol Psychiatry 43:2-11.
19. 1A receptor agonism. Schizophrenia Bull 31:305.
20. 1A receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 164:1411-1417.
21. Meltzer HY, Li Z, Kaneda Y, and Ichikawa J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Progr Neuro-psychopharmacol Biol Psychiatry 27:1159-1172.
22. 3 receptors: I. Receptorial, electrophysiological, and neurochemical profile compared with GR218231 and L741626. J Pharmacol Exp Ther 293:1048-1062.
23. Millan MJ, Loiseau F, Dekeyne A, Gobert A, Flik G, Cremers T, Rivet J-M, Sicard D, Billiras R, and Brocco M (2008) S33138 [N-[4-[2-[(3aS, 9bR)-8c-ciano-1,3a,4,9btetrahydro[ 1]-benzopyrano[3,4-c]pyrrol-2(3 H)-yl)ethyl]phenacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects. J Pharmacol Exp Ther 324:1212-1226.
24. Nakai S, Hirose T, Uwahodo Y, Imaoka T, Okazaki H, Miwa T, Nakai M, Yamada S, Dunn B, Burris KD, et al. (2003) Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol and risperidone. Eur J Pharmacol 472: 89-97.
25. Nordstedt C and Fredholm BB (1990) A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. Anal Biochem 189:231-234.
26. Olbrich R and Schanz H (1991) An evaluation of the partial dopamine agonist terguride regarding the positive symptoms reduction in schizophrenia. J Neural Transm Gen Sect 84:233-236.
27. 3 receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 294:1154-1165.
28. 2 receptor in schizophrenia. Exp Opin Ther Targets 10:515-531.
29. Shahid M, Walker GB, Zorn SH, and Wong EHF (2009) Asenapine: a novel psychopharmacologic agent with unique human receptor signature. J Psychopharmacol 23:65-73.
30. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR Roth BL, and Mailman RB (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411.
31. Sokoloff P, Diaz J, Levesque D, Pilon C, Dimitriadou V, Griffon N, Lammers CH, Martres MP, and Schwartz J-C (1995) Novel dopamine receptor subtypes as targets for antipsychotic drugs. Ann NY Acad Sci 757:278-292.
32. 3) as a target for neuroleptics. Nature 347:146-151.
33. Svensson K, Ekman A, Piercey MF, Hoffman W, Lum JT, and Carlsson A (1991) Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912, and terguride on central monoamine receptors. Naunyn Schmiedebergs Arch Pharmacol 344:263-274.
34. Tadori Y, Forbes RA, McQuade RD, and Kikuchi T (2008) Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol 597:27-33.
35. 2 receptors. Eur J Pharmacol 607:35-40.
36. Tadori Y, Miwa T, Tottori K, Burris KD, Stark A, Mori T, and Kikuchi T (2005) Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Phamacol 515:10-19.
37. 2 receptor-mediated signaling pathways. Neuropsychopharmacology 32:67-77.
38. Wainscott DB, Lucaites VL, Kursar JD, Baez M, and Nelson DL (1996) Pharmacological characterization on the human 5-hydroxytyptamine2B receptor: evidence for species differences. J Pharmacol Exp Ther 276:720-726.
39. Walters JR and Roth RH (1976) Dopaminergic neurons: an in vivo system for measuring drug interactions with presynaptic receptors. Naunyn Schmiedebergs Arch Pharmacol 296:5-14.
40. Yamauchi H, Miura M, Ichinose M, Ishikawa J, Nakajima N, Tomaki M, Inoue H, Maeyama K, Watanabe T, and Shirato K (1994) Involvement of apamin-sensitive K-channels in antigen-induced spasm of isolated guinea-pig trachea. Br J Pharmacol 112:958-962.